Tevimbra (tislelizumab-jsgr)

P2, N=134, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=7, Recruiting, Shanghai Changzheng Hospital | Not yet recruiting --> Recruiting

To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.

P3, N=123, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting

P2, N=76, Not yet recruiting, University Health Network, Toronto

BETINA study demonstrated promising efficacy and favorable tolerance in treating patients with mTNBC with bevacizumab with tislelizumab and nab-paclitaxel.

P1/2, N=202, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Oct 2026

P1, N=10, Recruiting, First Affiliated Hospital of Chongqing Medical University

P2, N=16, Active, not recruiting, Grupo Español Multidisciplinar de Melanoma | Trial completion date: May 2024 --> Aug 2025

P3, N=172, Not yet recruiting, Asan Medical Center

P2, N=30, Not yet recruiting, Fudan University

P2, N=92, Recruiting, Fudan University | Not yet recruiting --> Recruiting

Our data provide novel insights for anti-PD-1 treatment selection using NOTCH1 mutations and may provide a rationale for combination therapy in ESCC.

P2, N=30, Not yet recruiting, Liaoning Cancer Hospital & Institute

Despite the patient's PD-1 negativity, the combination of anlotinib and tislelizumab may exert synergistic effects through distinct mechanisms, thereby potentially enhancing therapeutic efficacy. The integration of a multi-targeted tyrosine kinase inhibitor within this combination therapy regimen warrants further investigation.

P=N/A, N=32, Not yet recruiting, The Third Affiliated Hospital Sun Yat-sen University; The Third Affiliated Hospital Sun Yat-sen University

P=N/A, N=60, Not yet recruiting, Gansu Provincial Cancer Hospital; Gansu Provincial Cancer Hospital

P2, N=46, Not yet recruiting, The Affiliated Panyu Central Hospital, Guangzhou Medical University; The Affiliated Panyu Central Hospital, Guangzhou Medical University

P2, N=40, Not yet recruiting, Shanxi Cancer Hospital; Shanxi Cancer Hospital

P2, N=20, Recruiting, Tianjin Third Central Hospital; Tianjin Third Central Hospital

P2, N=38, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

P=N/A, N=24, Not yet recruiting, The Third Affiliated Hospital of Sun Yat-sen University; The Third Affiliated Hospital of Sun Yat-sen University

P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital of Bengbu Medical College; The First Affiliated Hospital of Bengbu Medical College

P2, N=30, Not yet recruiting, West China Hospital , Sichuan University; West China Hospital , Sichuan University

P2, N=25, Recruiting, Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center

P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University

P2, N=25, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi

P1, N=60, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

P2, N=27, Not yet recruiting, Cancer Hospital Affiliated of Shandong First Medical University; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shando

P2, N=20, Active, not recruiting, Beijing Friendship Hospital | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> Dec 2024

P3, N=920, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting

P3, N=650, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Dec 2029 | Trial primary completion date: Jun 2025 --> Jun 2029

P2, N=35, Not yet recruiting, National Cheng-Kung University Hospital

P2, N=134, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

P2, N=28, Active, not recruiting, Seoul National University Hospital | Recruiting --> Active, not recruiting

P2, N=204, Terminated, Novartis Pharmaceuticals | Completed --> Terminated; The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not support the trial's purpose.

P1, N=157, Active, not recruiting, BeiGene | Trial completion date: Mar 2025 --> Oct 2026 | Trial primary completion date: Mar 2025 --> Oct 2025

P1, N=80, Recruiting, The First Affiliated Hospital of Zhengzhou University

P1, N=55, Terminated, BeiGene | Active, not recruiting --> Terminated; Sponsor decision

P3, N=430, Enrolling by invitation, BeiGene | N=300 --> 430

P=N/A, N=61, Recruiting, CHA University

Although there was a lower proportion of SCC (72.58% vs. 89.06%, P=0.02) and a lower use of paclitaxel (75.81% vs. 96.88%, P=0.004) in the pembrolizumab group in the overall cohort, the baseline characteristics between two groups were balanced in the SCC cohort. This real-world evidence study supports the non-inferiority of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in terms of efficacy and safety in patients with resectable NSCLC. We believe that our findings could be an important reference for future studies comparing pembrolizumab- and tislelizumab-based treatment combinations in the neoadjuvant setting.